CT based radiomic approach on first line pembrolizumab in lung cancer

Abstract Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marta Zerunian, Damiano Caruso, Alberto Zucchelli, Michela Polici, Carlo Capalbo, Marco Filetti, Federica Mazzuca, Paolo Marchetti, Andrea Laghi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/18a7ae47de7d4a85ad1c5f7dd80511e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18a7ae47de7d4a85ad1c5f7dd80511e2
record_format	dspace
spelling	oai:doaj.org-article:18a7ae47de7d4a85ad1c5f7dd80511e22021-12-02T13:24:15ZCT based radiomic approach on first line pembrolizumab in lung cancer10.1038/s41598-021-86113-52045-2322https://doaj.org/article/18a7ae47de7d4a85ad1c5f7dd80511e22021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86113-5https://doaj.org/toc/2045-2322Abstract Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with first line Pembrolizumab. Twenty-one patients with NSLC were prospectively enrolled; they underwent contrast enhanced CT (CECT) at baseline and during Pembrolizumab treatment. Response to therapy was assessed both with clinical and iRECIST criteria. Two radiologists drew a volume of interest of the tumor at baseline CECT, extracting several texture parameters. ROC curves, a univariate Kaplan-Meyer analysis and Cox proportional analysis were performed to evaluate the prognostic value of texture analysis. Twelve (57%) patients showed partial response to therapy while nine (43%) had confirmed progressive disease. Among texture parameters, mean value of positive pixels (MPP) at fine and medium filters showed an AUC of 72% and 74% respectively (P < 0.001). Kaplan-Meyer analysis showed that MPP < 56.2 were significantly associated with lower OS and PFS (P < 0.0035). Cox proportional analysis showed a significant correlation between MPP4 and OS (P = 0.0038; HR = 0.89[CI 95%:0.83,0.96]). In conclusion, MPP could be used as predictive imaging biomarkers of OS and PFS in patients with NSLC with first line immune treatment.Marta ZerunianDamiano CarusoAlberto ZucchelliMichela PoliciCarlo CapalboMarco FilettiFederica MazzucaPaolo MarchettiAndrea LaghiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Marta Zerunian Damiano Caruso Alberto Zucchelli Michela Polici Carlo Capalbo Marco Filetti Federica Mazzuca Paolo Marchetti Andrea Laghi CT based radiomic approach on first line pembrolizumab in lung cancer
description	Abstract Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with first line Pembrolizumab. Twenty-one patients with NSLC were prospectively enrolled; they underwent contrast enhanced CT (CECT) at baseline and during Pembrolizumab treatment. Response to therapy was assessed both with clinical and iRECIST criteria. Two radiologists drew a volume of interest of the tumor at baseline CECT, extracting several texture parameters. ROC curves, a univariate Kaplan-Meyer analysis and Cox proportional analysis were performed to evaluate the prognostic value of texture analysis. Twelve (57%) patients showed partial response to therapy while nine (43%) had confirmed progressive disease. Among texture parameters, mean value of positive pixels (MPP) at fine and medium filters showed an AUC of 72% and 74% respectively (P < 0.001). Kaplan-Meyer analysis showed that MPP < 56.2 were significantly associated with lower OS and PFS (P < 0.0035). Cox proportional analysis showed a significant correlation between MPP4 and OS (P = 0.0038; HR = 0.89[CI 95%:0.83,0.96]). In conclusion, MPP could be used as predictive imaging biomarkers of OS and PFS in patients with NSLC with first line immune treatment.
format	article
author	Marta Zerunian Damiano Caruso Alberto Zucchelli Michela Polici Carlo Capalbo Marco Filetti Federica Mazzuca Paolo Marchetti Andrea Laghi
author_facet	Marta Zerunian Damiano Caruso Alberto Zucchelli Michela Polici Carlo Capalbo Marco Filetti Federica Mazzuca Paolo Marchetti Andrea Laghi
author_sort	Marta Zerunian
title	CT based radiomic approach on first line pembrolizumab in lung cancer
title_short	CT based radiomic approach on first line pembrolizumab in lung cancer
title_full	CT based radiomic approach on first line pembrolizumab in lung cancer
title_fullStr	CT based radiomic approach on first line pembrolizumab in lung cancer
title_full_unstemmed	CT based radiomic approach on first line pembrolizumab in lung cancer
title_sort	ct based radiomic approach on first line pembrolizumab in lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/18a7ae47de7d4a85ad1c5f7dd80511e2
work_keys_str_mv	AT martazerunian ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT damianocaruso ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT albertozucchelli ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT michelapolici ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT carlocapalbo ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT marcofiletti ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT federicamazzuca ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT paolomarchetti ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer AT andrealaghi ctbasedradiomicapproachonfirstlinepembrolizumabinlungcancer
_version_	1718393078190964736

CT based radiomic approach on first line pembrolizumab in lung cancer

Ejemplares similares